A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions.

Autor: Dankwa S; Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America., Kosman C; Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America., Dennis M; Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America., Giorgi EE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America., Vuong K; Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America., Pahountis I; Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America., Garza A; Department of Surgery, Duke University School of Medicine, Durham, NC, United States of America.; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States of America., Binuya C; Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America., McCarthy J; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, United States of America.; Center for Human Systems Immunology, Duke University, Durham, NC, United States of America., Mayer BT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America., Ngo JT; Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, United States of America., Enemuo CA; Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, United States of America., Carnathan DG; Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, United States of America., Stanfield-Oakley S; Department of Surgery, Duke University School of Medicine, Durham, NC, United States of America.; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States of America., Berendam SJ; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States of America., Weinbaum C; Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America., Engelman K; Department of Medicine, UMass Chan Medical School, Worcester, MA, United States of America., Magnani DM; Department of Medicine, UMass Chan Medical School, Worcester, MA, United States of America., Chan C; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, United States of America.; Center for Human Systems Immunology, Duke University, Durham, NC, United States of America., Ferrari G; Department of Surgery, Duke University School of Medicine, Durham, NC, United States of America.; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States of America., Silvestri G; Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, United States of America.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, United States of America., Amara RR; Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, United States of America.; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, United States of America., Chahroudi A; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America.; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and Emory University, Atlanta, GA, United States of America., Permar SR; Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America.; Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medicine, New York, NY, United States of America., Fouda GG; Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America.; Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medicine, New York, NY, United States of America., Goswami R; Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America.; Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medicine, New York, NY, United States of America.

Publikováno v: PloS one [PLoS One] 2024 Nov 11; Vol. 19 (11), pp. e0312411. Date of Electronic Publication: 2024 Nov 11 (Print Publication: 2024).

Engineered ClearColi™-derived outer membrane vesicles as functional carriers for development of HIV-1 therapeutic vaccine candidate.

Autor: Sadeghi L; Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran., Bolhassani A; Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. Electronic address: azam.bolhassani@yahoo.com., Mohit E; Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: el_mohit@yahoo.com., Baesi K; Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran., Aghasadeghi MR; Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran., Milani A; Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran., Agi E; Iranian Comprehensive Hemophilia Care Center, Tehran, Iran.

Publikováno v: Microbial pathogenesis [Microb Pathog] 2024 Aug; Vol. 193, pp. 106749. Date of Electronic Publication: 2024 Jun 13.

Galectin-3, Galectin-9, and Interleukin-18 Are Associated with Monocyte/Macrophage Activation and Turnover More so than Simian Immunodeficiency Virus-Associated Cardiac Pathology or Encephalitis.

Autor: Ding AK; Department of Biology, Boston College, Chestnut Hill, Massachusetts, USA., Wallis ZK; Department of Biology, Boston College, Chestnut Hill, Massachusetts, USA., White KS; Department of Biology, Boston College, Chestnut Hill, Massachusetts, USA., Sumer CE; Department of Biology, Boston College, Chestnut Hill, Massachusetts, USA., Kim WK; Division of Microbiology, Tulane National Primate Research Center, Tulane University, Covington, Louisiana, USA.; Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Ardeshir A; Division of Microbiology, Tulane National Primate Research Center, Tulane University, Covington, Louisiana, USA.; Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Williams KC; Department of Biology, Boston College, Chestnut Hill, Massachusetts, USA.

Publikováno v: AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2024 Sep; Vol. 40 (9), pp. 531-542. Date of Electronic Publication: 2024 Jun 12.

Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.

Autor: Boopathy AV; Clinical Virology, Gilead Sciences, Inc., Foster, California, USA., Nekkalapudi A; Clinical Virology, Gilead Sciences, Inc., Foster, California, USA., Sung J; Drug Metabolism, Gilead Sciences, Inc., Foster, California, USA., Schulha S; Virology, Hookipa Pharma Inc., New York, New York, USA., Jin D; Protein Therapeutics, Gilead Sciences, Inc., Foster, California, USA., Sharma B; Discovery Virology, Gilead Sciences, Inc., Foster, California, USA., Ng S; Oncology, Gilead Sciences, Inc., Foster, California, USA., Lu S; Protein Therapeutics, Gilead Sciences, Inc., Foster, California, USA., Wimmer R; Virology, Hookipa Pharma Inc., New York, New York, USA., Suthram S; Bioinformatics, Gilead Sciences, Inc., Foster, California, USA., Ahmadi-Erber S; Virology, Hookipa Pharma Inc., New York, New York, USA., Lauterbach H; Global Research and Development, Hookipa Pharma Inc., New York, New York, USA., Orlinger KK; Global Research and Development, Hookipa Pharma Inc., New York, New York, USA., Hung M; Protein Therapeutics, Gilead Sciences, Inc., Foster, California, USA., Carr B; Drug Metabolism, Gilead Sciences, Inc., Foster, California, USA., Callebaut C; Clinical Virology, Gilead Sciences, Inc., Foster, California, USA., Geleziunas R; Clinical Virology, Gilead Sciences, Inc., Foster, California, USA., Kuhne M; Oncology, Gilead Sciences, Inc., Foster, California, USA., Schmidt S; Virology, Hookipa Pharma Inc., New York, New York, USA., Falkard B; Clinical Virology, Gilead Sciences, Inc., Foster, California, USA.

Publikováno v: Journal of virology [J Virol] 2024 Jul 23; Vol. 98 (7), pp. e0029424. Date of Electronic Publication: 2024 Jun 03.

Indoleamine-2,3-dioxygenase inhibition improves immunity and is safe for concurrent use with cART during Mtb/SIV coinfection.

Autor: Singh B, Sharan R, Ravichandran G, Escobedo R, Shivanna V, Dick EJ Jr, Hall-Ursone S, Arora G, Alvarez X, Singh DK, Kaushal D, Mehra S

Publikováno v: JCI insight [JCI Insight] 2024 Jul 02; Vol. 9 (15). Date of Electronic Publication: 2024 Jul 02.